MAM
LGND icon

Martingale Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Martingale Asset Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.55M Sell
17,562
-200
-1% -$47.1K 0.13% 163
2026
Q1 		$3.55M Buy
17,762
+2,440
+16% +$483K 0.09% 219
2025
Q4 		$2.9M Sell
15,322
-3,150
-17% -$605K 0.07% 244
2025
Q3 		$3.27M Sell
18,472
-1,681
-8% -$250K 0.08% 206
2025
Q2 		$2.29M Buy
20,153
+1,101
+6% +$118K 0.06% 277
2025
Q1 		$2M Buy
19,052
+960
+5% +$109K 0.05% 300
2024
Q4 		$1.94M Buy
18,092
+270
+2% +$30.5K 0.05% 318
2024
Q3 		$1.78M Sell
17,822
-2,200
-11% -$221K 0.04% 341
2024
Q2 		$1.69M Sell
20,022
-11,757
-37% -$936K 0.04% 341
2024
Q1 		$2.32M Sell
31,779
-180
-0.6% -$13.3K 0.05% 265
2023
Q4 		$2.28M Sell
31,959
-165
-0.5% -$9.74K 0.05% 258
2023
Q3 		$1.92M Buy
32,124
+3,853
+14% +$254K 0.04% 274
2023
Q2 		$2.04M Buy
28,271
+16,380
+138% +$1.23M 0.04% 272
2023
Q1 		$875K Buy
+11,891
New +$845K 0.02% 477
2019
Q2 		– Sell
-7,055
Closed -$554K – 1039
2019
Q1 		$554K Sell
7,055
-18,596
-72% -$1.41M 0.01% 875
2018
Q4 		$2.17M Sell
25,651
-483
-2% -$51.5K 0.03% 514
2018
Q3 		$4.48M Buy
26,134
+2
+0% +$302 0.05% 338
2018
Q2 		$3.38M Hold
26,132
– – 0.04% 412
2018
Q1 		$2.69M Sell
26,132
-321
-1% -$31.7K 0.03% 452
2017
Q4 		$2.26M Buy
26,453
+14,269
+117% +$1.24M 0.03% 503
2017
Q3 		$1.03M Buy
+12,184
New +$965K 0.01% 717
2016
Q4 		– Sell
-8,336
Closed -$531K – 989
2016
Q3 		$531K Buy
+8,336
New +$612K 0.01% 800

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Martingale Asset Management's LGND Position: Q2 2026 in Review

Martingale Asset Management reduced its Ligand Pharmaceuticals (LGND) stake by 1.1% in Q2 2026, selling an estimated $47.1K and leaving 17,562 shares worth $5.55M. The position accounts for 0.13% of the portfolio, ranked #163.

Martingale Asset Management first reported a position in LGND in Q3 2016 and has held it in 22 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Martingale Asset Management held 17,562 shares of Ligand Pharmaceuticals worth $5.55M as of Q2 2026.
  • Martingale Asset Management sold 200 Ligand Pharmaceuticals shares in Q2 2026, an estimated $47.1K.
  • Ligand Pharmaceuticals made up 0.13% of Martingale Asset Management's portfolio in Q2 2026, its #163 holding.
  • Martingale Asset Management first reported a position in Ligand Pharmaceuticals in Q3 2016 and has held it in 22 quarters since.
  • 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.